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824-4 Echocardiographic Findings in Patients Undergoing 
Percutaneous Aortic Valve Replacement
Fabrice Bauer, Hélène Eltchaninoff, Christophe Tron, Carla Agatiello, Laurent Sebagh, 
Alain Cribier, Hôpital Charles Nicolle, Rouen, France
Background: Percutaneous valve replacement (PVR) has been recently shown to be fea-
sible in human. A new percutaneous heart valve (PHV) made of 3 leaflets of equine peri-
cardium inserted in a stainless steel stent was successfully implanted within the native
diseased valve of 5 non-operable Pts (4 males, mean aged 75+12) with end stage calcific
aortic stenosis (AS). Assessment by transthoracic and transesophageal echocardio-
graphy of PHV function within the native diseased calcific valve are reported.
Methods and Results: Functional aortic valve area (AVA) by continuity equation, mean
trans-PHV pressure gradient (MG) and left ventricular ejection fraction (LVEF) were mea-
sured before, immediately post-PVR and sequentially during follow-up. Results are
shown in the table (* p<0,05 as compared to baseline).
Overtime, there was no PHV dislodgment, no change in paravalvular leak (mild in 3,
severe in two) noted post-PVR and PHV leaflets remained thin and mobile within a cylin-
drical stent frame.
Conclusions: Transthoracic and transesophageal echocardiography are the optimal way
to assess PHV function after PVR. Immediate and sustained valvular function and hemo-
dynamic improvements were observed, making this new technique promising for non-
surgical Pts with AS.
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824-5 Percutaneous Aortic Valve Replacement With a Self-
Expandable Stent-Valve in the Beating Heart: In Vivo 
Stress Testing in an Animal Model
Markus Ferrari, Gerhard Hellige, Markus Schlosser, Gerald S. Werner, Ines Frerichs, 
Christoph Damm, Volker Guyenot, Hans R. Figulla, Friedrich-Schiller-University, Jena, 
Germany, Georg-August-University, Goettingen, Germany
Introduction: Due to an increasing number of elderly patients with relevant co-morbidity
there is need for a non-invasive technique of aortic valve replacement. Therefore, we
evaluated the feasibility of percutaneous aortic valve replacement without cardiac arrest
in animal experiments.
Methods: Pulmonary valves from pigs were sutured in a self-expanding stent after low-
pressure fixation in Glutaraldehyd solution. The Nitinol stent, containing the biological
valve in its proximal part, was implanted in six pigs (88-118 kg) by means of a 25F cathe-
ter via the left subclavian artery by guidance of fluoroscopy and trans-esophageal
echocardiography (TEE). The original aortic valve was pushed against the aortic wall by
the self-expanding stent during the implantation.
Results: It was possible to replace the aortic valve in the beating heart without any com-
plication or even relevant drops in blood pressure in 4 pigs (67 %) . The procedure failed
in 2 pigs (33 %) due to failure of the catheter device in one case, and due to problems
with the correct positioning in the left ventricular outflow tract in the other case. The first
pig died of bleeding complications, the second pig died of an acute aortic insufficiency. In
the remaining four pigs we infused catecholamines: Cardiac output doubled compared to
baseline conditions. Heart rate increased to 158 +/-31 /min., and aortic pressure reached
149+/-3.4 mmHg. We did not observe any relevant aortic insufficiency by TEE, nor an
increase of peak aortic flow above 1.7 m/s.
Conclusion: This study proves the feasibility of percutaneous aortic valve replacement in
the beating heart, and shows the safety of the device under pathophysiologic stress con-
ditions. By further diameter reduction of the implantation-catheter-device, and chronic
animal experiments this concept might become a feasible option for treating patients with
relevant aortic valve disease but a high operative risk.
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824-6 Percutaneous Implantation of a Heart Valve: An Animal 
Study
David Paniagua, Eduardo Induni, Orlando Puente, Carlos Mejia, Carolyne Ortiz, Jose A. 
Condado, Manuel Velez, Martha Borbon, Elizabeth Gonzalez, R. David Fish, 
Endoluminal Technology Research, Miami Beach, FL, Texas Heart Institute/ St Luke's 
Episcopal Hosptial, Houston, TX
Background. 
Percutaneous heart valve (PHV) implantation is an emerging form of therapy for valve
disease. We developed a new low profile folded pericardial PHV deliverable with catheter
techniques. The initial acute and long term animal data is described.
Methods
Eleven sheep and six calves weighing 30 to 60 kg underwent transcatheter implantation
of a PHV. Vascular access via the femoral or carotid artery was employed. Introduction of
the PHV was performed using a customized delivery system and angiographic guidance.
Transthoracic Echo-Doppler assessment was used.
Results 
Eight chronic and 9 acute animal studies were performed. The PHV was implanted in the
descending aorta (11 animals), and in the ascending aorta (6 animals). Deployment of
the PHV in the selected position was made under fluoroscopic guidance using a balloon
expandable stent in one case and a self-expanded stent in 16 cases oversized by 10% to
have the required radial force to hold the valve in place without migration. No migration of
the stented valves has occurred. Pathological examination of the implantation site
showed ecchymosses and superficial hemorrhage without evidence of perforation or dis-
section. One animal died acutely of vascular complications. One stent did not open caus-
ing aortic thrombosis and death of the animal. One calf was sacrificed 3 weeks after
implantation. Function of the harvested PHV was competent in the left heart simulator
and histology showed no evidence of rejection. One calf is 8 months post implant of a self
expanded stented valve that has grown with him, he is clinically well. In the last 4 sheep,
the PHV was introduced through the carotid artery and placed in the ascending aorta.
Valves placed in this anatomical area are responsible for preventing leakage of 2/3 of the
diastolic pressure. The sheep recovered in less than 2 hours. These sheep are 3 months
post procedure in good clinical conditions and the valves are functioning properly by Dop-
pler study that shows forward flow without evidence of regurgitation.
Conclusion
Percutaneous implantation of this new PHV is feasible and well tolerated in sheep and
calf models, and show normally competent hemodynamic behaviour. Long term histology
is to follow.
POSTER SESSION
1125 New Concepts in the Management of 
Patients With Aortic Valve Disease
Tuesday, March 09, 2004, 9:00 a.m.-11:00 a.m.
Morial Convention Center, Hall G
Presentation Hour: 9:00 a.m.-10:00 a.m.
1125-135 Valve Renovation in Calcific Aortic Stenosis: Safety and 
Feasibility of a Novel Endoaortic System for Native 
Valve Preservation
Jerome B. Riebman, Kevin L. Ohashi, Robert D. Poser, Gerry J. Berry, Ajit P. Yoganathan, 
Corazon Technologies, Inc., Menlo, CA, Stanford University, Stanford, CA
BACKGROUND – Mineral removal using a low-pH saline solution treatment (demineral-
ization) may be a safe, predictable repair technique for calcified stenotic aortic valves
(AVs). In vivo and ex vivo safety and efficacy of an endoaortic system for in situ treatment
of calcified stenotic AVs was investigated.
METHODS – Excised human AV leaflets (n = 24) and intact calcified stenotic AVs (n=12)
were treated with demineralization solution in stages for up to 60 minutes. Treated leaf-
lets underwent biochemical and histological analysis to determine ex vivo safety.
Endoaortic treatment efficacy in intact AVs was assessed by pre- and post-treatment
hemodynamic, radiographic, and video motion analysis in a flow loop at multiple levels of
physiologic loading. Mineral removed and total mineral content of specimens was quanti-
fied using atomic absorption spectroscopy. In vivo safety was assessed in an ovine
model by exposing their normal AVs (n = 18) to the demineralization solution with the
endoaortic system ( 30 minutes) followed by serial cardiac echocardiography and histol-
ogy up to 9 months.
RESULTS – Human leaflet histology revealed preserved normal tissue architecture. Bio-
chemical analysis of primary and secondary structural elements (collagen, elastin)
showed no evidence of modification (Fourier Transform IR Spectroscopy and Differential
Scanning Calorimetry), degradation (High Performance Liquid Chromatography) or
increased enzyme degradation susceptibility. The hemodynamic function of the stenotic
AVs was improved (increased effective orifice areas up to 34.5±10.1% and decreased
transvalvular pressure gradients up to 46.2±9.9%). These changes were associated with
mineral removal (up to 117.0 ± 75.1 mg). Ovine AVs revealed some leaflet thinning and
slight regurgitation, of no clinical significance, through 9 months follow-up.
CONCLUSIONS – Mineral removal from calcified stenotic AVs improves leaflet mobility
and reduces transvalvular gradients while preserving tissue structure. Efficacy and safety
of in situ AV treatment has been demonstrated in both ex vivo and in vivo models. Effec-
tive calcified AV repair can be accomplished with an endoaortic treatment system.
1125-136 Predictive Factors of Peri and Post Operative Outcome 
After Valve Replacement in Patients With Critical Aortic 
Stenosis and Very Low Ejection Fraction
Bruno Vaquette, Herve Corbineau, Marcel Laurent, Bernard Lelong, Thierry Langanay, 
Christian de Place, Jean Philippe Verhoye, Christophe leclercq, Jean-Claude Daubert, 
Alain Leguerrier, University Hospital Rennes, Rennes, France
Background: Critical aortic stenosis with severe left ventricular systolic dysfunction
(LVSD) is classically associated with a high operative mortality. Moreover post-operative
LVSD reversibility is uncertain and difficult to predict. The aim of this restrospective study
was to identify the predictive factors of post-operative mortality and LVSD reversibility.
Methods and results: From 1990 to 2000, 155 consecutive pts (72±9 yrs) underwent
aortic valve replacement [AVR] for critical AS (mean gradient: 43±13 mmHg), with severe
LVSD (LVEF<30%). 138 pts were in NYHA class III-IV.
The peri-operative (30-day) mortality rate was 12%. NYHA class III-IV (p=0,004), cardio-
thoracic ratio > 0.6 [CTR] (p< 0, 0001), left bundle branch block (p=0,03) and renal insuf-
ficiency (p=0,001) were found as predictors of peri-operative mortality in univariate analy-
sis. At multivariate analysis, the only predictive factor was CTR >0,6 (p=0,002).
Pre PHV Post PHV 1-week follow-up
AVA (cm2) 0.57 ± 0.15 1.67 ± 0.15 * 1.54 ± 0.22 *
MG (mmHg) 29 ± 9 8 ± 3 * 12 ± 3 *
LV EF (%) 24 ± 9 31 ± 5 * 39 ± 7 *
